Status:
COMPLETED
A New Conception About Individualized Treatment Allocation for HCC
Lead Sponsor:
Tang-Du Hospital
Collaborating Sponsors:
Air Force Military Medical University, China
Army Medical University, China
Conditions:
HCC
Transarterial Chemoembolization
Eligibility:
All Genders
18-100 years
Brief Summary
The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider...
Detailed Description
Given that liver resection (LR) and transarterial chemoembolization (TACE) are the mainstay curative and palliative therapies for HCC, respectively, patients who underwent LR or TACE were included in ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Diagnosed with HCC
- Receiving LR or TACE therapy
- Complete clinical information
- Preserved liver function (Child-Pugh Score \[CPS\] ≤ 7)
- PS 0-1
- Exclusion Criteria
- Vascular invasion or extrahepatic spread;
- Ecompensated liver cirrhosis ;
- Younger than 18 years;
- Duration of follow-up of fewer than 30 days.
Exclusion
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
4991 Patients enrolled
Trial Details
Trial ID
NCT06008548
Start Date
January 1 2010
End Date
October 1 2021
Last Update
August 23 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.